STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say
Pharma companies that make GLP-1 drugs have increasingly promoted telehealth companies that prescribe the popular treatments. With a new deal announced this week, one of those relationships is expected to grow more complicated. Eli Lilly has been featuring a telehealth company called Counsel Health on a list of providers for patients seeking a GLP-1 prescription. On Tuesday, Counsel said it would be acquired by the smart ring maker Oura, allowing Counsel clinicians access to the data gathered th...
Read full article →